Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of ipilimumab via lymphatic drug delivery with nivolumab in recurrent or metastatic head and neck squamous cell carcinoma
jRCTs021250037Phase 1Recruiting
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab and nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Japan Society for the Promotion of Science. Primary endpoint: Primary safety endpoint. Started Apr 2026; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCTs021250037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021250037.